Back

The SGLT2 inhibitor era: what more can we expect?

1 September 2019 (13:35 - 13:50)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes Diabetes and the Heart ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

4 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor T. Luescher (London, GB)
Slides Video
Presentation thumbnail
The role of SGLT2 inhibitors in CV risk reduction in patients with type 2 diabetes
Professor S. Kaul (Los Angeles, US)
Slides Video
Presentation thumbnail
Taking the initiative: the cardiologist´s perspective
Professor N. Marx (Aachen, DE)
Slides Video
Presentation thumbnail
Audience questions and answers, summary and close
Professor T. Luescher (London, GB)
Video

Access the full session

Session thumbnail
SGLT2 inhibitors in clinical cardiology: modern-day cardiovascular management in patients with type 2 diabetes

The Event

Event poster

ESC Congress 2019

1 September 2019 13:35 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors for obesity
31 August 2024
thumbnail
Congress Presentation
Contemporary use of iSGLT2 in heart transplant patients: indications and safety
20 May 2023
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024
thumbnail
Congress Presentation
Sodium-glucose cotransporter-2 inhibitors and their combination with glucagon like peptide-1 receptor agonists improve endothelial glycocalyx and arterial stiffness in type-2 diabetes
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources